Exhibit 99.2

1 Fighting Cancer with Precision Gammabody ™ Platform Corporate Presentation September 2022

2 Legal Disclosure: Forward - looking Statements This presentation contains forward - looking statements, including with respect to the company’s anticipated growth and clinical development plans, including the timing of clinical trials . Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward - looking statements . These forward - looking statements are based on LAVA’s expectations and assumptions as of the date of this presentation and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward - looking statements . Forward - looking statements contained in this presentation include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets . Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody ™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates . The COVID - 19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity . In addition, there may be adverse effects on our business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine . LAVA assumes no obligation to update any forward - looking statements contained herein to reflect any change in expectations, even as new information becomes available .

3 Investment Highlights Clinical - Stage Company Developing Bispecific Gamma Delta T Cell Engagers © LAVA Therapeutics 2022 • Gammabody ™ Platform - Bispecific antibodies linking V  9V  2 T cells to tumor targets to l everage the unique anti - tumor potential of V  9V  2 T cells • Strongly enhance tumor cell killing while retaining tumor specificity • Advantages: Low risk for on - target/off - tumor toxicity, co - activation of suppressor T cells and cytokine release syndrome Approach • Two programs in Phase 1/2a trials, initial data released ASCO 2022, additional data read - outs later in 2022 and 2023 Clinical Stage Company • First investigational products from product concept to clinical trial in 5 years Team that Delivers • $110.7M (Q2 2022) in cash and investments; c ash runway greater than two years • Collaborations with Janssen (J&J) and Seagen Well - funded

4 Differentiated Gammabody ™ Pipeline in Hematologic & Solid Tumor Indications Solid Tumor Hematologic malignancy MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate - specific membrane antigen EGFR: epidermal growth factor receptor mCRPC : metastatic castration - resistant prostate cancer © LAVA Therapeutics 2022 Candidate Target Indication(s) Discovery Preclinical Phase 1 Phase 2 Phase 3 Milestones LAVA - 051 CD1d MM CLL AML • Phase 1 data 2Q 2022 (ASCO) • Additional data in 2H 2022/1H 2023 LAVA - 1207 PSMA mCRPC • Phase 1 data Q1 2023 (ASCO GU) • Phase 2a expansion cohort data 1H 2023 LAVA - 1223 EGFR Solid Tumors • Licensed to Seagen Sept 2022 LAVA - 1266 CD123 Hematologic Malignancies • IND / CTA filing expected YE 2023 LAVA - 1278 CD40 Hematologic Malignancies Janssen Biotech Collaboration undisclosed

5 Established Leadership with Proven Experience in Drug Discovery & Development Ton Adang, PhD CDO Paul Parren, PhD EVP, Head of R&D Hans van der Vliet, MD, PhD CSO Steve Hurly, MSc, MBA President & CEO • 25+ years leadership experience in life sciences industry • Former President & CEO, Sesen Bio, a NASDAQ - listed oncology biotech • Veteran in strategic drug development • 15+ years investment banking experience • Industry leader in antibody science and drug development • Former Head of Preclinical Development & Research, Genmab • Inventor of five marketed therapeutic antibodies, including a bispecific • Vast experience inventing, developing therapeutic antibodies and technologies, including DARZALEX & DuoBody • Medical oncologist, professor at the Department of Medical Oncology, Amsterdam UMC • Inventor of LAVA’s gamma delta T cell engager platform • Extensive experience as clinical investigator Benjamin Winograd, MD, PhD CMO • Expertise in drug development programs in hematology and oncology, including several successful regulatory filings • Former roles at Bristol - Myers Squibb, Pharmacia, Schering - Plough & Celgene • Previous Head of Clinical R&D for Multiple Myeloma, Celgene • Vast experience in drug development • Former roles at Organon, Schering - Plough & Merck/MSD • Leadership positions in Lead Discovery and Project Management (i.e., Merck’s KEYTRUDA) • Extensive global, diversified legal and team building experience; 15+ years practicing law • Most recently Associate General Counsel, Spark Therapeutics (Roche), serving as a strategic advisor for U.S. launch of first gene therapy • Previously at Sandoz (Novartis) and Ballard Spahr LLP as business and transactional attorney Amy Garabedian General Counsel © LAVA Therapeutics 2022

6 Gamma Delta T Cells Uniquely suited for an anti - cancer T cell engager approach V  9V  2 T Cells

7 V  9V  2 T Cells are Uniquely Positioned to Leverage Innate & Adaptive Immunity V  9V  2 T cells are an abundant, homogeneous effector cell population associated with positive outcomes in cancer patients Adaptive Immunity Innate Immunity Yeung MM, et al. Gut 2000; 47:215 Kimura Y, et al. Cancer Sci 2016; 107:1206 Lo Presti , et al, Front Immunol 2014; 5:1 Wu P, et al. Immunity 2014;40:785 Adams EJ, et al. Annu Rev Immunol 2013; 31:529 Lo Presti E, et al. Cancer Immunol Res 2017; 5:397 Adapted from Dranoff G., Nature Rev. Cancer 2004; 4: 11 - 22 V  2 T cells • Natural ability to recognize and kill tumor cells • Highly cytotoxic • Largest  - T cell subset: ~90 - 95% in peripheral blood • Monomorphic TCR: V  2 preferentially pairs with V  9 • Well - defined specificity: phosphoantigen - BTN2A1/3A1 complex • Consistent proinflammatory cytotoxic effector T cell population • Unique antigen presenting ability – potential for durable response • Positive association with outcome in cancer patients Pang DJ, et al. Immunology 2012; 136:283 Adams EJ, et al. Cell Immunol 2015; 296:31 Siegers GM, et al. Mol Ther 2014; 22:1416 © LAVA Therapeutics 2022

8  T Cells Present in Many Cancers & Correlated With Favorable Prognosis Adapted from Tosolini M et al. Oncoimmunology 2017; 6, e1284723  T cells indicate highest correlation with favorable outcome among all leukocyte subsets analyzed V  9V  2 T cells are present across a wide array of hematological and solid malignancies Abundance of Tumor - Infiltrating Vg9Vd2 T Cells Adapted from Gentles A et al, Nature Medicine 2015; 21:938 - 945 * In vivo/ex vivo data generated using Lava’s  - bsTCEs Unweighted [meta - 2] Leukocytes Ranked By Survival Hematological Malignancies Solid Tumors  (Abundance) N=5,782 Tumors ■ Favorable ■ Adverse Global Prognostics Associations for 22 Leukocyte Types Across 25 Cancers © LAVA Therapeutics 2022

9 LAVA’s Proprietary Gammabody ™ Platform Bispecific Gamma Delta T Cell Engagers

10 Systemic Activation of V  9V  2 T Cells Showed Promise • Systemic activation and proliferation via treatment with V  9V  2 T cell - based therapy (synthetic phosphoantigens ( BrHPP ) / aminobisphosphonates ± low - dose IL - 2) Early attempts with V  9V  2 T cell - based therapy showed promise, but efficacy may have been limited by systemic, non - tumor specific activation of V  9V  2 T cells and exhaustion in vivo activation ex vivo activation • Clinical trials with in/ex vivo activation protocols showed promising objective responses and safety • No signs of cytokine release syndrome (CRS) as a result of V  9V  2 T cell activation cell transfer therapy isolation of  T cells Tumor Pre - Treatment Post - Treatment Lung metastases of RCC; adoptive transfer Lymphoma; NBP / IL - 2 Kobayashi H et al., Cancer Immunol Immunother 2011; 60: 1075 - 1084 Wilhelm M et al., Blood 2003; 102: 200 - 206 © LAVA Therapeutics 2022

11 Off - the - Shelf Gammabody ™ Platform: Enhances Innate Tumor Recognition by Directing V  9V  2 T Cells to the Cancer Cells LAVA’s Gammabody ™ adds tumor antigen - specific recognition, while retaining stress signal recognition, to target and activate V  9V  2 T cells to induce both direct tumor cell killing and orchestrate an immunological cascade of anti - cancer responses V  9V  2 T cells recognize stress signals – TCR interacts with pAg - butyrophilin complex Conditionally activate V  9V  2 T cells upon crosslinking with tumor associated antigen (TAA) Gammabody ™ Provides Tumor Recognition to Trigger V  9V  2 T Cell - Mediated Immunity 1 2 Retains recognition of natural stress signals Natural Activation Mechanism V  9V  2 TCR Gammabody ™ TAA butyrophilin V  9V  2 T cell V  9V  2 T cell Tumor cell butyrophilin Tumor cell V  9V  2 TCR 1 pAg pAg © LAVA Therapeutics 2022

12 Cascade Response – Potential Translation to Favorable Therapeutic Window Efficacy: Safety: In addition to direct tumor cell killing , V  9 V  2 T cells have the potential to orchestrate an immunological cascade response that includes activation of innate and adaptive immune cells in the tumor microenvironment • Potent killing of cancer cells (EC 50 s in the low picomolar range) • No co - activation of immune - suppressive Tregs which dampen antitumor efficacy of cytotoxic T cells • Orchestrate innate and adaptive immune responses, potentially resulting in potent and durable responses • Activity against hematologic malignancies and solid tumors, including immunologically “cold” tumors • Potential for expansion of V  9V  2 T cells can result in an increased number of anti - tumor V  9V  2 T cells in the tumor • Conditional activation with high accuracy • Greatly reduced potential for cytokine release syndrome (CRS); No evidence of CRS in NHP studies Adapted from Dranoff G, Nature Rev Cancer 2004; 4: 11 - 22 Kabelitz D et al., Cell Mol Immunol 2020; 17: 925 – 939 © LAVA Therapeutics 2022

13 Potent Killing of Cancer Cells in Preclinical Models Highly Potent Durable Dose Dependent and Serial Killing Conditional Activation EGFR Gammabody ™ - Induced Cytotoxicity CD1d Gammabody ™ Triggers Lysis of CCRF - CEM Tumor Cells Killing of Primary Colorectal Cancer Cells by EGFR Gammabody ™ Sustained EGFR Gammabody ™ - Mediated Killing of Tumor Cells by V  9V  2 T Cells de Bruin RC et al., OncoImmunology 2017; 7: e1375641, right bottom Data on file: LAVA Therapeutics N.V. , top row and left bottom © LAVA Therapeutics 2022

14 Expansion & Cascade Response Without Treg Activation in Preclinical Models Gammabody ™ can induce robust gamma delta T cell expansion and can amplify the anti - tumor immune response via downstream activation of other immune cells while avoiding co - activation of immunosuppressive T cells such as Tregs Expansion No Treg Activation Cascade Response Gammabody ™ - Mediated Expansion of V  9V  2 T Cells no bsTCE CD1d Gammabody ™ CD40 Gammabody ™ A431 Treg EGFR - CD3 TCE EGFR Gammabody ™ PBMC + tumor + tumor + EGFR Gammabody ™ N=4; *: p<0.05, **: p<0.01 © LAVA Therapeutics 2022 Data on file: LAVA Therapeutics N.V.

15 Gammabody ™ Can Selectively Kill Cancer Cells W hile Sparing Healthy Cells in Hematologic Malignancy and Solid Tumor models • 2:1 ratio (  T cells : Target cells) • Similar CD20 expression levels on C1R neo and B - cells CD20 Gammabody ™ Mediated Killing PSMA Gammabody ™ Mediated Killing Preferential killing of cancer versus healthy cells demonstrated in vitro and ex vivo ; may prevent on - target/off - tumor mediated toxicity and allow for targeting of widely expressed tumor associated antigens **** p<0.001 Prostate Cancer Normal Prostate Medium + PSMA Gammabody ™ + V  9V  2 T cells + V  9V  2 T cells + PSMA Gammabody ™ © LAVA Therapeutics 2022 Data on file: LAVA Therapeutics N.V.

16 Fully Cross - Reactive  bsTCEs are Well - Tolerated in Non - Human Primates • Mild to no clinical signs of toxicity • Low cytokine spike, which did not result in CRS • No clinical chemistry abnormalities • No histopathological abnormalities • Gammabody ™ detectable on peripheral blood and lymph node gamma delta T cells NHP data support the potential benign safety profile of LAVA’s Gammabody ™ platform CD1d - , CD20 - targeting surrogate Gammabody TM (without Fc ) were dosed up to 10 mg/kg (4 hr infusion, 4 doses, every 2 days) and biweekly at 1 mg/kg for 1 month EGFR - targeting surrogate Gammabody ™ (without Fc ) was dosed up to 10 mg/kg (4 hr infusion, 4 doses, every 2 days) EGFR - targeting surrogate Gammabody ™ ( Fc - containing ) was dosed up to 23 mg/kg (0.5 hr infusion, 4 weekly doses) © LAVA Therapeutics 2022 Data on file: LAVA Therapeutics N.V.

17 LAVA - 051 Activates  T Cells and iNKT Cells by Targeting CD1d for the Treatment of CLL, MM & AML

18 LAVA - 051: First - in - Class Gammabody ™ Targeting CD1d • Principal Mechanism of Action ( MoA ): Targets and activates V  9V  2 T cells in the presence of CD1d - expressing tumor cells • Secondary MoA : Activates iNKT cells against CD1d - expressing tumor cells ‒ Direct cytotoxicity against CD1d - positive tumor cells ‒ Promotes the cytotoxic activity of V  9V  2 T cells and iNKT cells Tumor Cell iNKT Cell V  9V  2 T Cell  TCR CD1d β 2 m • Enrollment underway in Phase 1/2a clinical trial ‒ MM, CLL, and, at higher dose levels, AML ‒ Initial data disclosed ASCO 2022 ‒ Additional data expected in 4Q 2022 • Potential accelerated approval pathways available iNKT TCR © LAVA Therapeutics 2022

19 LAVA - 051: Targeting CD1d for Hematological Cancers CD1d is expressed on tumors cells in a high proportion of patients with CLL, MM & AML CD1d expression (MF index) Isotype Isotype Isotype 0.5 1 2 4 8 16 32 64 128 N=39 N=51 N=85 AML MM CLL © LAVA Therapeutics 2022 Data on file: LAVA Therapeutics N.V.

20 CLL AND MM AML (highest dose levels only) Optional adjustments: • Dosing frequency • Dose level • # cohorts CLL (n=20) MM (n=20) Twice - weekly dosing AML (n=20) LAVA - 051 Phase 1/2a Initiated in Hematological Malignancies Phase 1 first 4 cohorts dose escalation data presented at ASCO 2022; Additional data is expected in 4Q 2022; Dose Escalation Dose Expansion Recommended expansion dose/schedule n = estimated number of patients per indication Goal: Determine preliminary level of activity per disease Goal: Determine recommended dose and schedule based on optimal biological dose or maximum tolerated dose (MTD) © LAVA Therapeutics 2022

21 Biomarker analysis to validate whether LAVA’s Gammabody ™ platform performs in humans as predicted based on preclinical data LAVA - 051 Phase 1/2a: Extensive Biomarker Analysis Pharmacodynamics Cytokines (IL - 1β, IL - 2, IL - 6, IL - 8, TNF - α, IFN - γ, GM - CSF) B inding of LAVA - 051: V  9V  2 - T cells | CD1d positive tumor cells Activation status & frequency: V  9V  2 - T cells | iNKT cells Induction of activation of V  9V  2 - T cells ex vivo when exposed to CD1d (functional assay) Immune - monitoring ( frequency and activation status of B cells , T cell subsets , NK cells , monocytes, dendritic cells ) Disease assessments Tumor - defining markers/CD1d/BTN3A - MM (peripheral blood, urine, CT scan, bone marrow biopsy) - CLL (peripheral blood, CT scan, bone marrow biopsy) - AML (peripheral blood, bone marrow biopsy) Safety Chemistry / hematology / urine Pharmaco k inetics A nti - D rug A ntibodies © LAVA Therapeutics 2022

22 LAVA - 051 - Patient characteristics and time on treatment MM/CLL 3/3 Male/Female 5/1 Median age (range) 66 (60 - 75) Prior therapies, median (range) – MM/CLL 5 (4 - 6) 4 (3 - 5) DLT period PD PD PD PD COVID COVID © LAVA Therapeutics 2022

23 LAVA - 051 - Adverse events NS = not suspected; S = suspected A : Drug hypersensitivity Gr3 reported for CLL patient to allopurinol administered as TLS prophylaxis; allergy to allopurinol con firmed through repeat occurrence to single agent prophylaxis. B : Fever Gr2 reported for CLL patient in conjunction with 'tumor flare’. C : Diverse electrolyte imbalances reported for MM patient: hypercalcemia Gr3 and hypomagnesemia Gr2 reported 2 days following 1s t treatment - discontinuation of calcium carbonate and colecalciferol , all resolved; hypophosphatemia Gr2 reported 14 days following 1st treatment - all resolved; hypokalemia Gr2 reported 21 days followi ng 1st treatment - resolved. D : Neutropenia Gr3 reported for MM patient 14 days following first treatment - readily resolved with one dose of pegfilgrastim . E : Infusion related reaction Gr2 within 15 minutes of end of infusion; no reappearance during following infusions administered f ollowing clemastine and paracetamol prophylaxis. Data cut - off date of presented data was 2 May 2022 • Overall well tolerated • No CRS • No ICANS • No DLTs Cycle 1 Worst grade per patient TEAE Grade ≥2 0.45  g (N=1) 3  g (N=1) 15  g (N=1) 45  g (N=3) Total (N=6) Relatedness AE NS S NS S NS S NS S Bone pain 1 1 Cancer pain 1 1 Contrast media allergy 1 1 Decreased appetite 1 1 Diarrhea 1 1 Drug hypersensitivity 1 A 1 Dyspnea exertional 1 1 Fatigue 1 1 Hypercalcemia 1 C 1 Hypoalbuminemia 1 1 Hypokalemia 1 C 1 Hypomagnesemia 1 C 1 Hypophosphatemia 1 C 1 Infusion related reaction 1 E 1 Lumbar vertebral fracture 1 1 Motor dysfunction 1 1 Neutropenia 1 1 D 2 Pain in extremity 1 1 Pyrexia 1 B 1 Rhinitis 1 1 © LAVA Therapeutics 2022

24 LAVA - 051 - Pharmacodynamics • V  9 V  2 T cell activation markers (CD 25 and CD 69 ) consistently upregulated following dosing, in each dose cohort • Maximum measured V  9 V  2 T cell receptor occupancy (RO) increased with higher dose cohorts • iNKT cell activation was assessable, and observed, in one patient (cohort 2 ) • No significant increase in the CRS - related cytokine IL - 6 = dosing = missed dose Dose/ patient ID V  9 V  2 T cell frequency (% of CD3+) % CD25+ V  9 V  2 - T cells Baseline Post - dosing (range) Baseline Post - dosing (max) 0.45  g/03 - 001 0.00 ND ND ND 3  g/02 - 001 0.51 0.31 - 0.74 18.2 51.5 15  g/02 - 002 1.46 0.02 - 1.08 0.9 7.9 45  g/03 - 003 0.41 0 - 0.42 15.2 35.6 45  g/01 - 001 0.45 0 - 0.10 12.5 55.6 45  g/02 - 003 0.05 0 - 0.07 0 50.0 © LAVA Therapeutics 2022

25 LAVA - 051 – Potential signs of activity 0 25 50 75 100 125 0.01 0.1 1 Treatment days Cell count (x10 9 /L) Lymphocytes Clonal B cells R/R = Relapsed/Refractory; iwCLL = international workshop on C hronic Lymphocytic L eukemia. Permission for photo obtained. MM • High risk MM patient ( 45  g) • 4 prior lines of therapy within 6 years from diagnosis : – Bortezomib, Cyclo , Dex → auto HSCT – Carfilzomib, Lenalidomide, Dex – Pomalidomide, Dex – Daratumumab, Dex • Refractory to last 3 lines of treatment • 23 % reduction in M - protein • Patient stopped due to COVID CLL • Patient with R/R CLL ( 15  g) : temporary enlargement and tenderness of several involved lymph nodes accompanied by grade 2 fever during Cycle 1 ; resembled a tumor - flare reaction • Other causes of enlargement of involved LNs ruled out • Patient assessed as having stable disease per iwCLL criteria ( 2018 ) • Percent of clonal B cells in peripheral blood decreased from 41 . 8 % at baseline to 8 . 9 % at the start of Cycle 4 • Patient stopped after Cycle 5 due to COVID © LAVA Therapeutics 2022

26 Conclusions • LAVA - 051 is the first of a novel class of bispecific  T cell engagers with expected broad therapeutic window – Bispecific single domain antibody engaging CD 1 d and V  2 - TCR chain of V  9 V  2 - T cells to mediate potent killing – Low potential for CRS observed in preclinical models and clinical setting when V  9 V  2 - T cells are activated • LAVA - 051 has safely reached 100x the starting dose in CLL and MM – No CRS and no ICANS (ASTCT) – No significant increase in the CRS - related cytokine IL - 6 – Most observed AEs have not been suspected to be related – No DLTs • No ADA’s detected to date • Predictable and linear pharmacokinetics • PD parameters reflect changes as expected per MoA – V  9 V  2 - T cell activation markers (CD 25 and CD 69 ) were consistently upregulated following dosing, in each dose cohort . – Maximum measured V  9 V  2 - T cell receptor occupancy increased with higher dose cohorts – iNKT cell activation was assessable, and observed, in one patient (cohort 2 ) • Preliminary signs of clinical activity in a CLL patient and MM patient • Trial continuing, including US sites (IND cleared) and evaluation of s.c. dosing ASTCT = American Society for Transplantation and Cellular Therapy ICANS = Immune Effector Cell Associated Neurotoxicity Syndrome DLT = Dose Limiting Toxicity ADA = Anti - Drug Antibody; MoA = Mechanism of Action © LAVA Therapeutics 2022

27 LAVA - 1207 Activates  T Cells by Targeting PSMA for the Treatment of mCRPC

28 LAVA - 1207: Targeting PSMA for Prostate Cancer PSMA + tumor cells LAVA - 1207 VHH - Fc ~80kD V  9V  2 T cells • Specifically targets and mediates activation of V  9 V  2 T cells against PSMA - expressing tumor cells • PSMA is a well - validated tumor target ‒ Mediates PSMA - dependent activation of V  9 V  2 T cells resulting in potent killing of PSMA - positive tumor cells • Fc added to extend half life, silenced to avoid Fc - mediated effector functions • Pre - clinical data support MoA , anti - cancer activity & selectivity • Phase 1 / 2 a trial advancing ; patient recruitment ongoing ‒ Metastatic castration - resistant prostate cancer ( mCRPC ) ‒ Initial Phase 1 data expected in 4 Q 2022 © LAVA Therapeutics 2022

29 LAVA - 1207 Phase 1/2a in Metastatic Castration - Resistant Prostate Cancer ( mCRPC ) Therapy Refractory mCRPC Optional Adjustments: • Dosing frequency • Dose level • # cohorts Therapy Refractory mCRPC (n=30) Dosing: Every 2 Weeks LAVA - 1207 Phase 1/2a Initiated; Patient Recruitment Underway Dose Escalation Dose Expansion Recommended expansion dose / schedule Goal: Determine preliminary level of activity Goal: Determine recommended dose and schedule based on MTD or optimal biological dose © LAVA Therapeutics 2022

30 Key Preclinical Programs

31 Potential for LAVA - 1223 Across a Number of EGFR - Expressing Solid Tumors Data on file: LAVA Therapeutics N.V. and Janssen Biotech Inc. 0 20 40 60 80 100 Bladder Breast Colon Glioma Head & Neck NSCLC Ovarian Pancreatic RCC Percentage overexpression range EGFR Expression by Tumor Type (Range) Sustained EGFR Gammabody ™ Mediated Killing of Tumor Cells by V  9V  2 T Cells EGFR Gammabody ™ Concentration (Log10 pM ) © LAVA Therapeutics 2022

32 LAVA - 1266 Shows Promise for Hematological Malignancies 0.01 0.1 1 10 100 1000 0 20 40 60 80 100 CD123 Gammabody TM Concentration [pM] Specific cell death of primary AML cells (%) EC50 ~ 8 pM 0.01 0.1 1 10 100 1000 0 20 40 60 80 100 CD123 Gammabody TM Concentration [pM] THP-1 cell line cytotoxicity (%) EC50 ~ 3 pM Potent L ysis of AML Cell L ine and P rimary AML Cells by CD123 Gammabody ™ CD123 is Overexpressed in a Wide Range of Hematological Malignancies • AML • B - ALL • Hairy cell leukemia • Hodgkin lymphoma • Blastic plasmacytoid dendritic cell neoplasm • B - cell chronic lymphoproliferative disorders • MDS CD123 expression FSC CD123 expression on AML cells © LAVA Therapeutics 2022 Data on file: LAVA Therapeutics N.V.

33 Milestones

34 • 3L+ mCRPC pts • Adoptive FIH study design, dose escalation • Key data: Safety, initial anti - tumor activity, estimation of therapeutic window • Initial study in relapsed/refractory MM, CLL; relapsed/refractory AML added at biological relevant dose(s) • Adoptive FIH study design, dose escalation • Key data: Safety, initial anti - tumor activity, estimation of therapeutic window 2H22 1H22 Two Lead Programs in Clinic with Near - Term Milestones Cash runway greater than two years Phase 1: Initial Dose Escalation in 4Q 2022 1H23 Additional clinical data in 4Q 2022 Additional clinical data 2H 2023 LAVA - 051 (CD1d) LAVA - 1207 (PSMA) Phase 1 Dose Escalation (ASCO) © LAVA Therapeutics 2022

35 Corporate Presentation September 2022